Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

Open Access 01-12-2021 | Obesity | Research article

Natural course of metabolically healthy phenotype and risk of developing Cardiometabolic diseases: a three years follow-up study

Authors: Daniel Elías-López, Arsenio Vargas-Vázquez, Roopa Mehta, Ivette Cruz Bautista, Fabiola Del Razo Olvera, Donaji Gómez-Velasco, Paloma Almeda Valdes, Carlos A. Aguilar-Salinas, for the Metabolic Syndrome Study Group

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

Whether the metabolically healthy obese (MHO) phenotype is a single, stable or a transitional, fluctuating state is currently unknown. The Mexican-Mestizo population has a genetic predisposition for the development of type 2 diabetes (T2D) and other cardiometabolic complications. Little is known about the natural history of metabolic health in this population. The aim of this study was to analyze the transitions over time among individuals with different degrees of metabolic health and body mass index, and evaluate the incidence of cardiometabolic outcomes according to phenotype.

Methods

The study population consisted of a metabolic syndrome cohort with at least 3 years of follow up. Participants were apparently-healthy urban Mexican adults ≥20 years with a body mass index (BMI) ≥20 kg/m2. Metabolically healthy phenotype was defined using the criteria of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) metabolic syndrome criteria and the subjects were stratified into 4 groups according to their BMI and metabolic health. For cardiometabolic outcomes we estimated the incidence of cardiometabolic outcomes and standardized them per 1, 000 person-years of follow-up. Finally, to evaluate the risk for transition and development of cardiometabolic outcomes, we fitted Cox Proportional Hazard regression models.

Results

Amongst the 5541 subjects, 54.2% were classified as metabolically healthy and 45.8% as unhealthy. The MHO prevalence was 39.3%. Up to a third of the population changed from their initial category to another and the higher transition rate was observed in MHO (42.9%). We also found several novel factors associated to transition to metabolically unhealthy phenotype; socioeconomic status, number of pregnancies, a high carbohydrate intake, history of obesity and consumption of sweetened beverages. Similarly, visceral adipose tissue (VAT) was a main predictor of transition; loss of VAT ≥5% was associated with reversion from metabolically unhealthy to metabolically healthy phenotype (hazard ratio (HR) 1.545, 95%CI 1.266–1.886). Finally, we observed higher incidence rates and risk of incident T2D and hypertension in the metabolically unhealthy obesity (MUHO) and metabolically unhealthy lean (MUHL) phenotypes compared to MHO.

Conclusions

Metabolic health is a dynamic and continuous process, at high risk of transition to metabolically unhealthy phenotypes over time. It is imperative to establish effective processes in primary care to prevent such transitions.
Appendix
Available only for authorised users
Literature
4.
13.
go back to reference Eshtiaghi R, Keihani S, Hosseinpanah F, Barzin M, Azizi F. Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: the Tehran lipid and glucose study. Int J Obes. 2014;39(3):514–9.CrossRef Eshtiaghi R, Keihani S, Hosseinpanah F, Barzin M, Azizi F. Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: the Tehran lipid and glucose study. Int J Obes. 2014;39(3):514–9.CrossRef
16.
go back to reference Arellano-Campos O, Gómez-Velasco DV, Bello-Chavolla OY, et al. Development and validation of a predictive model for incident type 2 diabetes in middle-aged Mexican adults: the metabolic syndrome cohort. BMC Endocr Disord. 2019;19(1):41. https://doi.org/10.1186/s12902-019-0361-8. Arellano-Campos O, Gómez-Velasco DV, Bello-Chavolla OY, et al. Development and validation of a predictive model for incident type 2 diabetes in middle-aged Mexican adults: the metabolic syndrome cohort. BMC Endocr Disord. 2019;19(1):41. https://​doi.​org/​10.​1186/​s12902-019-0361-8.
17.
go back to reference Medina C, Barquera S, Janssen I. Validity and reliability of the international physical activity questionnaire among adults in Mexico. Rev Panam Salud Publica. 2013;34(1):21–8.PubMed Medina C, Barquera S, Janssen I. Validity and reliability of the international physical activity questionnaire among adults in Mexico. Rev Panam Salud Publica. 2013;34(1):21–8.PubMed
19.
go back to reference Bello-Chavolla O, Almeda-Valdes P, Gomez-Velasco D, Viveros-Ruiz T, Cruz-Bautista I, Romo-Romo A, et al. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol. 2018;178(5):533–44. https://doi.org/10.1530/EJE-17-0883. Bello-Chavolla O, Almeda-Valdes P, Gomez-Velasco D, Viveros-Ruiz T, Cruz-Bautista I, Romo-Romo A, et al. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol. 2018;178(5):533–44. https://​doi.​org/​10.​1530/​EJE-17-0883.
26.
go back to reference de Castro PA, Scorsatto M, Moraes de Oliveira G, Rosa G, Luiz R. Characterization of metabolically healthy obese Brazilians and cardiovascular risk prediction. Nutrition. 2015;31(6):827–33.CrossRef de Castro PA, Scorsatto M, Moraes de Oliveira G, Rosa G, Luiz R. Characterization of metabolically healthy obese Brazilians and cardiovascular risk prediction. Nutrition. 2015;31(6):827–33.CrossRef
31.
go back to reference Eckel N, Li Y, Kuxhaus O, Stefan N, Hu F, Schulze M. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' health study): 30 year follow-up from a prospective cohort study. Lancet Diab Endocrinol. 2018;6(9):714–24. https://doi.org/10.1016/S2213-8587(18)30137-2.CrossRef Eckel N, Li Y, Kuxhaus O, Stefan N, Hu F, Schulze M. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' health study): 30 year follow-up from a prospective cohort study. Lancet Diab Endocrinol. 2018;6(9):714–24. https://​doi.​org/​10.​1016/​S2213-8587(18)30137-2.CrossRef
32.
go back to reference Echouffo-Tcheugui J, Short M, Xanthakis V, Field P, Sponholtz T, Larson M, et al. Natural history of obesity subphenotypes: dynamic changes over two decades and prognosis in the Framingham heart study. J Clin Endocrinol Metab. 2018;104(3):738–52.CrossRef Echouffo-Tcheugui J, Short M, Xanthakis V, Field P, Sponholtz T, Larson M, et al. Natural history of obesity subphenotypes: dynamic changes over two decades and prognosis in the Framingham heart study. J Clin Endocrinol Metab. 2018;104(3):738–52.CrossRef
42.
go back to reference Schulze M. Metabolic health in normal-weight and obese individuals. Diabetologia. 2018;62(4):558–66.CrossRef Schulze M. Metabolic health in normal-weight and obese individuals. Diabetologia. 2018;62(4):558–66.CrossRef
45.
go back to reference Aguilar Salinas CA. Atención primaria. Modelo de control y atención a la salud. In: Rivera Dommarco JA, Colchero MA, Fuentes ML, González de Cosío Martínez T, Aguilar Salinas CA, Hernández Licona G, Barquera S, editors. La obesidad en México. Estado de la política pública y recomendaciones para su prevención y control. Cuernavaca: Instituto Nacional de Salud Pública, México; 2018. Aguilar Salinas CA. Atención primaria. Modelo de control y atención a la salud. In: Rivera Dommarco JA, Colchero MA, Fuentes ML, González de Cosío Martínez T, Aguilar Salinas CA, Hernández Licona G, Barquera S, editors. La obesidad en México. Estado de la política pública y recomendaciones para su prevención y control. Cuernavaca: Instituto Nacional de Salud Pública, México; 2018.
Metadata
Title
Natural course of metabolically healthy phenotype and risk of developing Cardiometabolic diseases: a three years follow-up study
Authors
Daniel Elías-López
Arsenio Vargas-Vázquez
Roopa Mehta
Ivette Cruz Bautista
Fabiola Del Razo Olvera
Donaji Gómez-Velasco
Paloma Almeda Valdes
Carlos A. Aguilar-Salinas
for the Metabolic Syndrome Study Group
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00754-1

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine